Continuous treatment with @entity4546 20 mg daily for up to 6 years in XXXX .

@entity1 @entity4546 @entity355
BACKGROUND: Because of the malignant potential of @entity355 , an aim of treatment is to cause the columnar epithelium to regress. A logical approach is to decrease acid reflux which is an important aetiological factor in @entity355 . Treatment with @entity4546 20-80 mg over 1-3 years has yielded conflicting but largely disappointing results. AIM: To determine if treatment of @entity355 with @entity4546 20 mg daily for up to 6 years can cause regression of the Barrett's epithelium. @entity1 AND METHODS: Forty-seven @entity1 with @entity355 were treated in an open prospective study. Nine @entity1 were treated for 2 years, 12 for 3 years, 10 for 4 years, eight for 5 years and eight for 6 years. @entity1 were endoscoped at 1-2-year intervals and endoscoped at the end of the treatment period. RESULTS: No significant shortening of the length of the Barrett's segment was seen during any treatment period, although @entity4546 controlled reflux symptoms and was well tolerated. Macroscopic squamous islands appeared in 55% of @entity1 , mostly in the first 2-3 years although in five @entity1 they appeared later in treatment. CONCLUSION: Treatment of @entity355 with @entity4546 20 mg daily for periods of up to 6 years did not cause regression in the length of the Barrett's segment, but it did lead in over half of the @entity1 to partial re-epithelialization in the form of squamous islands.
